Abstract
Background: The fact that mucopolysaccharidoses (MPSes) are now treatable, and that the earlier treatment is initiated the better, is an indication for neonatal screening. The most efficient approach seems likely to be a multi‐tier procedure in which screening for urinary glycosaminoglycan (GAG) is followed by enzyme determinations in heelprick blood of newborns screening positive. Hitherto the method of choice for the determination of GAG has been the measurement of absorbance by a complex of GAG and 1,9‐dimethylmethylene blue (DMB). Method: We evaluated a DMB method in which absorbance by DMB is measured following its addition to the eluate obtained from paper‐borne newborn urine samples and is normalized relative to urinary creatinine. Calibration is performed with chondroitin‐6‐sulfate (Ch‐6‐S). Results: The limits of detection and quantification of GAG were 1.98 and 5.94 mg/dl, respectively. The within‐run coefficients of variation (CVs) of the GAG/creatinine ratio for 25, 31, and 70 mg/dl solutions of Ch‐6‐S in urine were 21.8, 16.4, and 10.5%, respectively, and the corresponding between‐run CVs were 25.0, 13.5, and 10.1%. Recovery from the urine spiked with 31 mg Ch‐6‐S/dl was 94.8%. Accuracy was also acceptable for all other GAGs except hyaluronic acid. For neonatal screening, the diagnostic threshold was tentatively established as 800 mg GAG/g creatinine, the 95th centile of samples from 903 infants aged 3–28 days, but the value of the GAG/creatinine ratio was negatively correlated with age. Application of the new method to samples from older individuals with and without MPS achieved 100% sensitivity and specificity when used with an age‐dependent threshold taken from the literature on the original DMB method. Conclusion: If used in the first tier of a multi‐tier screening protocol, the proposed method would allow the detection of abnormal levels of all GAGs except hyaluronic acid. J. Clin. Lab. Anal. 24:149–153, 2010. © 2010 Wiley‐Liss, Inc.
Keywords: newborn screening, lysosomal disorders, mucopolysaccharidoses, DMB reagent, urine in paper specimen
REFERENCES
- 1. Berry HK. Procedures for testing urine specimens dried on filter paper. Clin Chem 1959;5:603–608. [PubMed] [Google Scholar]
- 2. Berry HK. Screening for mucopolysaccharide disorders with the Berry Spot Test. Clin Biochem 1987;20:365–371. [DOI] [PubMed] [Google Scholar]
- 3. Sabater J, Villalba M, Maya A. Mass screening of newborns for mucopolysaccharidoses. Clin Genet 1973;4:260–263. [DOI] [PubMed] [Google Scholar]
- 4. Whitley CB, Draper KA, Dutton CN, Brow PA, Severspn SL, France LA. Diagnostic test for mucopolysaccharides. II. Rapid quantification of glycosaminoglycan in urine samples collected on paper matrix. Clin Chem 1989;35:2074–2081. [PubMed] [Google Scholar]
- 5. Humbel R, Etringer S. A colorimetric method for the determination of sulphated glycosaminoglycans. Rev Roum Biochem 1974;11:21–24. [Google Scholar]
- 6. Whitley CB, Spielman RC, Herro G, Teragawa SS. Urinary glycosaminoglycan excretion quantified by an automated semimicro method in specimens conveniently transported from around the globe. Mol Genet Metab 2002;75:56–64. [DOI] [PubMed] [Google Scholar]
- 7. Matern D. Newborn screening for lysosomal storage disorders. Acta Paediatr 2008;97:33–37. [DOI] [PubMed] [Google Scholar]
- 8. Thuy LP, Nyhan WL. A new quantitative assay for glycosaminoglycans. Clin Chim Acta 1992;212:17–26. [DOI] [PubMed] [Google Scholar]
- 9. Fraga JM, Alonso‐Fernández JR, Bóveda MD, Cocho JA, Bravo M, Peña J. The organization and methods of neonatal and metabolic screening in the regional screening centre of Galicia (Spain) In: Therrel BL, Jr, editor. Advances in Neonatal Screening. Excerpta Medica; 1987, p 481–483. [Google Scholar]
- 10. Woolf LI. Large‐scale screening for metabolic disease in the newborn in Great Britain In: Anderson JA, Swaiman KF, editors. Phenylketonuria and allied metabolic diseases. Washington: Childrens Bureau; 1967, p 50–61. [Google Scholar]
- 11. Colomé Mallolas C, Quintana Berga M, Puig Quintana RM, Moreno García J, Vilaseca Buscá MA, Artuch Iriberri R. Determinación de glucosaminoglicanos en orina por un procedimiento espectrométrico. Valores de referencia para una población pediátrica. Química Clínica 1999;18:278–281. [Google Scholar]
- 12. Molinelli AR, Childs J, Shane‐Kumler K, Jack RM. A pediatric reference range for urinary glycosaminoglycans using the VITROS 5, 1FS chemistry system. Clin Chem 2007;53:A 209. [Google Scholar]
- 13. Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC) . Comité Científico. Comisión de Errores Metabólicos Congénitos. Document B, phase 3, version I. Prepared by I. Igueleor Guturbai, M. Espada Sáenz‐Torre, E. Dulin Iñiguez, F. Chamorro Ureña. Química Clínica 2006;25:36–44. [Google Scholar]
- 14. Iwata S, Sukegawa K, Kokuryo M, Tomatsu S, Kondo N. Glycosaminoglycans in neonatal urine. Arch Dis Child Fetal Neonatal Ed 2000;82:F78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Guías de Saúde Publica . Serie II: Sección E. Endocrinas e Metabólicas. Informe 3. Actualización do Programa Galego para a Detección de Enfermidades Endocrinas e Metabólicas en Período Neonatal. Resultados 1995–2005. Novembro 2006. Xunta de Galicia. Consellería de Sanidade. Dirección Xeral de Saúde Pública. Servicio de Programas Poblacionais de Cribado. Depósito Legal: C–3031–2006.
- 16. Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler‐like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem 2001;47:2098–2102. [PubMed] [Google Scholar]